Furthermore, the number of CD8-positive cells infiltrating the liver metastatic tumor was significantly higher in the dasatinib treatment and combination treatment groups than in the control and anti-PD-1 antibody treatment groups (p < 0.05; Figure 3h). This evidence concerns the gene PDCD1 and metastatic neoplasm.